South Korea · Delayed Price · Currency is KRW BioSmart Statistics
Total Valuation
BioSmart has a market cap or net worth of KRW 78.60 billion. The enterprise value is 145.27 billion.
| Market Cap | 78.60B |
| Enterprise Value | 145.27B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioSmart has 25.27 million shares outstanding. The number of shares has increased by 5.32% in one year.
| Current Share Class | 25.27M |
| Shares Outstanding | 25.27M |
| Shares Change (YoY) | +5.32% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 24.78% |
| Owned by Institutions (%) | 0.23% |
| Float | 18.75M |
Valuation Ratios
The trailing PE ratio is 44.45.
| PE Ratio | 44.45 |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | 3.87 |
| P/OCF Ratio | 2.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.00, with an EV/FCF ratio of 7.15.
| EV / Earnings | 84.26 |
| EV / Sales | 0.31 |
| EV / EBITDA | 5.00 |
| EV / EBIT | 6.99 |
| EV / FCF | 7.15 |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.91 |
| Quick Ratio | 0.51 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 2.48 |
| Debt / FCF | 3.48 |
| Interest Coverage | 5.65 |
Financial Efficiency
Return on equity (ROE) is 0.57% and return on invested capital (ROIC) is 5.32%.
| Return on Equity (ROE) | 0.57% |
| Return on Assets (ROA) | 4.49% |
| Return on Invested Capital (ROIC) | 5.32% |
| Return on Capital Employed (ROCE) | 9.97% |
| Revenue Per Employee | 2.77B |
| Profits Per Employee | 10.20M |
| Employee Count | 169 |
| Asset Turnover | 1.67 |
| Inventory Turnover | 7.20 |
Taxes
In the past 12 months, BioSmart has paid 5.70 billion in taxes.
| Income Tax | 5.70B |
| Effective Tax Rate | 86.28% |
Stock Price Statistics
The stock price has decreased by -11.81% in the last 52 weeks. The beta is 0.51, so BioSmart's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -11.81% |
| 50-Day Moving Average | 3,164.80 |
| 200-Day Moving Average | 3,224.85 |
| Relative Strength Index (RSI) | 51.03 |
| Average Volume (20 Days) | 74,753 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSmart had revenue of KRW 468.61 billion and earned 1.72 billion in profits. Earnings per share was 69.96.
| Revenue | 468.61B |
| Gross Profit | 83.71B |
| Operating Income | 20.20B |
| Pretax Income | 6.60B |
| Net Income | 1.72B |
| EBITDA | 28.50B |
| EBIT | 20.20B |
| Earnings Per Share (EPS) | 69.96 |
Balance Sheet
The company has 42.32 billion in cash and 70.61 billion in debt, giving a net cash position of -28.29 billion or -1,119.39 per share.
| Cash & Cash Equivalents | 42.32B |
| Total Debt | 70.61B |
| Net Cash | -28.29B |
| Net Cash Per Share | -1,119.39 |
| Equity (Book Value) | 174.01B |
| Book Value Per Share | 5,366.42 |
| Working Capital | 75.69B |
Cash Flow
In the last 12 months, operating cash flow was 27.00 billion and capital expenditures -6.69 billion, giving a free cash flow of 20.31 billion.
| Operating Cash Flow | 27.00B |
| Capital Expenditures | -6.69B |
| Free Cash Flow | 20.31B |
| FCF Per Share | 803.71 |
Margins
Gross margin is 17.86%, with operating and profit margins of 4.31% and 0.37%.
| Gross Margin | 17.86% |
| Operating Margin | 4.31% |
| Pretax Margin | 1.41% |
| Profit Margin | 0.37% |
| EBITDA Margin | 6.08% |
| EBIT Margin | 4.31% |
| FCF Margin | 4.33% |
Dividends & Yields
BioSmart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.32% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.19% |
| FCF Yield | 25.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2010. It was a reverse split with a ratio of 0.16667.
| Last Split Date | Sep 20, 2010 |
| Split Type | Reverse |
| Split Ratio | 0.16667 |
Scores
BioSmart has an Altman Z-Score of 2.89 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.89 |
| Piotroski F-Score | 7 |